Spectranetics Corp. (The) (SPNC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Spectranetics Corp. (The) (SPNC) trades at $38.45 with AI Score 55/100 (Grade B). Spectranetics Corporation, though historically focused on medical devices for vascular intervention, is no longer trading publicly after being acquired. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for SPNC: SPNC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SPNC against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SPNC: the 3 perspectives are evenly split.
Spectranetics Corp. (The) (SPNC) Healthcare & Pipeline Overview
Spectranetics Corporation, previously a key player in the medical device industry, developed and marketed innovative solutions for vascular intervention and cardiac care. While historically a publicly traded entity, the company's stock (SPNC) is no longer active following its acquisition, marking a shift in the competitive landscape of the medical device sector.
What Is the Investment Thesis for SPNC?
The investment thesis for Spectranetics Corporation is now historical, as the company is no longer publicly traded. Previously, key value drivers included its innovative laser atherectomy technology, strong gross margins at 74.8%, and a growing market for vascular intervention devices. Growth catalysts centered on expanding applications of its existing products, penetrating new geographic markets, and launching next-generation technologies. Potential risks included competition from larger medical device companies, regulatory hurdles, and the negative profit margin of -21.5%. Investors would have monitored revenue growth, market share gains, and the company's ability to maintain its technological edge. The beta of 1.65 indicated higher volatility compared to the market.
Based on FMP financials and quantitative analysis
SPNC Key Highlights
- Gross Margin of 74.8% reflects strong pricing power and efficient manufacturing processes.
- Negative Profit Margin of -21.5% indicates challenges in achieving profitability despite high gross margins.
- Beta of 1.65 suggests the stock was more volatile than the overall market.
- Focus on laser atherectomy provided a differentiated technology platform in the vascular intervention space.
- Global sales network enabled access to a large and growing market for medical devices.
Who Are SPNC's Competitors?
SPNC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BSX Boston Scientific Corporation | $46.12 | -2.23% | $68.55B | 56 |
| ABT Abbott Laboratories | $88.17 | -1.65% | $153.58B | 48 |
| MDT Medtronic plc | $80.20 | -0.16% | $102.97B | 56 |
| NPCE NeuroPace, Inc. | $15.89 | +0.32% | $541.75M | 65 |
| ATRWF Altius Renewable Royalties Corp. | $8.50 | +0.00% | $262.46M | 64 |
| LFTSF LifeTech Scientific Corporation | $0.23 | +0.00% | $1.03B | 63 |
| MYO Myomo, Inc. | $1.20 | -12.41% | $46.37M | 62 |
| MEDGF Medacta Group S.A. | $83.91 | +0.00% | $1.67B | 55 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SPNC's Key Strengths?
- Innovative laser atherectomy technology.
- Strong gross margins.
- Established global sales network.
- Focus on improving patient outcomes.
What Are SPNC's Weaknesses?
- Negative profit margin.
- Reliance on a limited number of products.
- High beta indicating volatility.
- Smaller size compared to major competitors.
What Could Drive SPNC Stock Higher?
- Continued adoption of laser atherectomy in vascular procedures.
- Expansion of product applications in new vascular conditions.
- Potential for new clinical data supporting the efficacy of Spectranetics' products (timeline unknown).
- Growth in the global market for vascular intervention devices.
What Are the Key Risks for SPNC?
- Competition from larger medical device companies with greater resources.
- Regulatory changes affecting the approval and reimbursement of medical devices.
- Technological advancements rendering Spectranetics' products obsolete.
- Economic downturns affecting healthcare spending and demand for medical devices.
- Product liability claims.
What Are the Growth Opportunities for SPNC?
- Expansion into Emerging Markets: Spectranetics had the opportunity to expand its sales and marketing efforts in emerging markets, where the prevalence of vascular disease is increasing and access to advanced medical technologies is growing. This expansion could involve establishing new distribution partnerships, conducting clinical trials, and tailoring products to meet the specific needs of local markets. The market size for medical devices in emerging markets is projected to reach $200 billion by 2028, offering significant growth potential.
- Development of Next-Generation Technologies: Spectranetics could invest in research and development to develop next-generation laser atherectomy systems with improved efficacy, safety, and ease of use. This could involve incorporating advanced imaging technologies, developing new catheter designs, and expanding the range of treatable conditions. The market for advanced medical imaging technologies is expected to reach $45 billion by 2027, creating opportunities for innovation and differentiation.
- Strategic Acquisitions: Spectranetics could pursue strategic acquisitions to expand its product portfolio, gain access to new technologies, and increase its market share. This could involve acquiring companies with complementary products or technologies in the vascular intervention or cardiac care space. The medical device industry is highly fragmented, with numerous small and medium-sized companies that could be attractive acquisition targets. These acquisitions could be completed within the next 3-5 years.
- Partnerships with Healthcare Providers: Spectranetics could establish partnerships with hospitals, clinics, and physician groups to provide comprehensive solutions for vascular and cardiac care. This could involve offering training programs, providing technical support, and developing customized treatment protocols. These partnerships could help to drive adoption of Spectranetics' products and improve patient outcomes. These partnerships could be formed within the next 1-2 years.
- Expanding Applications of Existing Products: Spectranetics could explore new applications for its existing products in the treatment of other vascular conditions, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). This could involve conducting clinical trials to demonstrate the safety and efficacy of its products in these new applications. The market for DVT and PE treatment is growing rapidly, driven by an aging population and increasing awareness of these conditions. This expansion could occur over the next 2-3 years.
What Opportunities Does SPNC Have?
- Expansion into emerging markets.
- Development of next-generation technologies.
- Strategic acquisitions.
- Partnerships with healthcare providers.
What Threats Does SPNC Face?
- Competition from larger medical device companies.
- Regulatory hurdles.
- Technological obsolescence.
- Economic downturns affecting healthcare spending.
What Are SPNC's Competitive Advantages?
- Proprietary laser atherectomy technology.
- Strong brand reputation in the vascular intervention space.
- Established relationships with key opinion leaders and healthcare providers.
- Extensive intellectual property portfolio.
What Does SPNC Do?
Spectranetics Corporation, prior to its acquisition, was a medical device company focused on developing, manufacturing, marketing, and distributing interventional devices used in procedures to treat or manage vascular disease, and in cardiac procedures. Founded with the vision of improving patient outcomes through advanced medical technologies, Spectranetics established itself as a leader in the field of laser atherectomy and related therapies. The company's products were used to treat a range of cardiovascular conditions, including peripheral artery disease (PAD) and coronary artery disease (CAD). Spectranetics' portfolio included a variety of specialized catheters, guidewires, and other devices designed to improve the efficacy and safety of interventional procedures. Its products were sold to hospitals, clinics, and physicians' offices worldwide. The company invested heavily in research and development to innovate and expand its product offerings. Spectranetics differentiated itself through its focus on laser technology and its commitment to providing comprehensive solutions for vascular and cardiac care. The company's historical headquarters were in Colorado Springs, Colorado. Spectranetics' growth was fueled by an aging population, increasing prevalence of vascular disease, and advancements in interventional techniques.
What Products and Services Does SPNC Offer?
- Developed and manufactured laser atherectomy systems for treating vascular disease.
- Offered a range of specialized catheters and guidewires for interventional procedures.
- Provided solutions for treating peripheral artery disease (PAD) and coronary artery disease (CAD).
- Marketed its products to hospitals, clinics, and physicians' offices worldwide.
- Invested in research and development to innovate and expand its product offerings.
- Focused on improving patient outcomes through advanced medical technologies.
How Does SPNC Make Money?
- Developing and manufacturing medical devices for vascular intervention and cardiac care.
- Selling its products directly to hospitals, clinics, and physicians' offices.
- Generating revenue through product sales and related services.
- Investing in research and development to innovate and expand its product portfolio.
What Industry Does SPNC Operate In?
Spectranetics operated within the medical device industry, specifically targeting the vascular intervention and cardiac care segments. This industry is characterized by innovation, regulatory scrutiny, and intense competition. Key trends include the increasing use of minimally invasive procedures, the development of advanced imaging technologies, and the growing demand for specialized devices to treat complex cardiovascular conditions. The market is driven by an aging population, rising prevalence of chronic diseases, and increasing healthcare spending. Spectranetics competed with larger, more diversified medical device companies, as well as smaller, specialized players. The company's focus on laser atherectomy provided a niche within this competitive landscape.
Who Are SPNC's Key Customers?
- Hospitals and clinics that perform vascular and cardiac procedures.
- Interventional cardiologists and vascular surgeons.
- Physicians who treat patients with vascular disease.
SPNC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Insiders seem to be holding steady, which could signal confidence in SPNC's long-term prospects despite recent market jitters.
- The buzz in the community suggests people believe SPNC is undervalued and poised for a rebound, seeing it as a hidden gem.
- There's a growing perception that SPNC's innovative tech could disrupt the medical device market, attracting more attention and investment.
- Recent market developments indicate increased demand for SPNC's specific medical solutions, potentially boosting their revenue streams.
Bear Case
- Community sentiment reveals concerns about increasing competition eroding SPNC's market share.
- The overall market perception is that SPNC faces regulatory hurdles that could delay product approvals and impact profitability.
- Some insiders may be quietly reducing their positions, which could indicate a lack of confidence in SPNC's immediate growth potential.
- Recent market developments suggest a potential slowdown in healthcare spending, which could negatively affect SPNC's sales.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SPNC Latest News
No recent news available for SPNC.
SPNC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SPNC.
Price Targets
Wall Street price target analysis for SPNC.
SPNC MoonshotScore
What does this score mean?
The MoonshotScore rates SPNC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Common Questions About SPNC (Healthcare)
What does Spectranetics Corp. (The) do?
Spectranetics Corporation, prior to its acquisition, was a medical device company specializing in the development, manufacturing, and marketing of interventional devices for treating vascular and cardiac conditions. Its core technology was laser atherectomy, a minimally invasive procedure used to remove plaque from arteries. The company offered a range of specialized catheters, guidewires, and other devices used in these procedures. Spectranetics' products were sold to hospitals, clinics, and physicians' offices worldwide, targeting the growing market for vascular intervention and cardiac care.
What do analysts say about SPNC stock?
Analyst opinions on SPNC stock are now historical, as the company is no longer publicly traded. Previously, analysts considered factors such as the company's revenue growth, gross margins, and market share in the vascular intervention space. Key valuation metrics included the price-to-sales ratio and earnings multiples. Growth considerations centered on the company's ability to expand its product portfolio, penetrate new geographic markets, and maintain its technological edge. The negative profit margin was a concern, while the high beta indicated greater volatility compared to the market. Analyst ratings and price targets are no longer relevant.
What are the main risks for SPNC?
The main risks for Spectranetics Corporation, prior to its acquisition, included competition from larger medical device companies with greater resources, regulatory hurdles affecting the approval and reimbursement of medical devices, and the potential for technological obsolescence. Economic downturns affecting healthcare spending and demand for medical devices also posed a risk. Additionally, product liability claims and the company's negative profit margin were significant concerns. These risks are now historical in the context of the company's current status.
What are the key factors to evaluate for SPNC?
Spectranetics Corp. (The) (SPNC) holds an AI score of 55/100 (moderate). Not financial advice.
How frequently does SPNC data refresh on this page?
SPNC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SPNC's recent stock price performance?
Spectranetics Corp. (The) (SPNC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative laser atherectomy technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SPNC overvalued or undervalued right now?
Valuing Spectranetics Corp. (The) (SPNC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SPNC?
Before investing in Spectranetics Corp. (The) (SPNC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on historical data prior to the company's acquisition.
- Financial data may not be current.
- AI analysis is pending.